Phase III Start For LG’s Biosimilar Humira In Crowded Korean Sector
This article was originally published in PharmAsia News
Competition is becoming ever fiercer in the South Korean biosimilars sector as LG Life Sciences begins late stage clinical development for another project, moving it a step closer to commercialization. Its biosimilar versions of Humira and Enbrel have also entered Phase III trials in Japan with local partner Mochida.
Register for our free email digests: